Research Progress on the Clinical Use and Safety of Bexagliflozin
Abstract
application value. Methods: Relevant domestic and international literature was retrieved, and existing studies on bexagliflozin were summarized. Results: Bexagliflozin is rapidly absorbed after oral administration and supports once-daily dosing. Its glucose-lowering efficacy is
non-inferior to dapagliflozin and remains consistent across different baseline HbA1c levels, as well as in elderly patients and those with chronic kidney disease (CKD). Accompanied by osmotic diuresis and caloric loss, it reduces blood pressure and body weight, without increasing
the risk of major adverse cardiovascular events (MACE), demonstrating cardiovascular safety non-inferior to other drugs in the same class.
Adverse reactions are most commonly genitourinary tract infections, while volume depletion and ketoacidosis, though rare, warrant vigilance.
Conclusion: Bexagliflozin has a generally manageable safety profile and provides an effective treatment option for type 2 diabetes mellitus
(T2DM). However, given its relatively short time on the market, long-term outcomes remain to be validated.
Keywords
Full Text:
PDFReferences
[1] BASSETT R L, GALLO G, LE K P N, VOLINO L R. Bexagliflozin: a comprehensive review of a recently approved SGLT2 inhibitor
for the treatment of type 2 diabetes mellitus[J]. Medicinal Chemistry Research, 2024, 33(8): 1354-1367. DOI: 10.1007/s00044-024-
03274-4.
[2] HALVORSEN Y D, WALFORD G, THURBER T, et al. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes[J]. Diabetes, Obesity and Metabolism, 2020,
22(4): 566-573. DOI: 10.1111/dom.13928.
[3] STACHEAS P, PATOULIAS D, POPOVIC D S, et al. Bexagliflozin as an adjunct therapy to diet and exercise to improve glycaemic
control in adults with type 2 diabetes[J]. touchREVIEWS in Endocrinology, 2024, 20(1): 19. DOI: 10.17925/EE.2024.20.1.6.
[4] HALVORSEN Y D, CONERY A L, LOCK J P, et al. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in
adults: a 24-week, randomized, double-blind, placebo-controlled trial[J]. Diabetes, Obesity and Metabolism, 2023, 25(10): 2954-2962.
DOI: 10.1111/dom.15192.
[5] MCMURRAY J J, SOLOMON S D, LOCK J P, et al. Meta-analysis of risk of major adverse cardiovascular events in adults with type 2
diabetes treated with bexagliflozin[J]. Diabetes, Obesity and Metabolism, 2024, 26(3): 971-979. DOI: 10.1111/dom.15394.
[6] KHAN N A, ARIF H, IMRAN L. A review of the safety and efficacy of bexagliflozin for the management of type 2 diabetes[J]. SN
Comprehensive Clinical Medicine, 2023, 5: 217. DOI: 10.1007/s42399-023-01563-4.
[7] AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE COMMITTEE. 9. Pharmacologic Approaches to Glycemic
Treatment: Standards of Care in Diabetes—2026[J]. Diabetes Care, 2026, 49(Supplement_1): S183-S215. DOI: 10.2337/dc26-S009.
[8] ZHOU Z J, ZHENG M, ZUO Z H, WU T. Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes
Mellitus: a meta-analysis[J]. ESC Heart Failure, 2024. DOI: 10.1002/ehf2.14726.
DOI: http://dx.doi.org/10.70711/pmr.v3i10.10085
Refbacks
- There are currently no refbacks.
